Zealand Pharma, a biopharmaceutical company, acquired cycle to develop peptide targeted drugs for inflammatory bowel disease

On October 23, 2019, the arterial network (wechat: vcpeat) learned through external media information that the Danish biopharma company, Zeland Pharma, announced to purchase the biotechnology company, encyletherapeutics (cycle) and its main candidate drug, et3764, for us $80 million Under the terms of the agreement, Zeland Pharma will acquire all intellectual property rights and issued shares of cycle, including the right to develop and commercialize potential assets The acquisition strengthens the leadership of Zeland Pharma in peptide drug development and gastrointestinal disease treatment Et3764 is an oral inhibitor targeting integrin α 4 β 7, which can be used in the treatment of inflammatory bowel disease (IBD) Integrins, also known as integrins, are a kind of heterophilic cell adhesion molecules that are commonly found on the cell surface of vertebrates The protein can mediate the recognition and adhesion between cells, between cells and extracellular matrix Integrin α 4 β 7 is a kind of core adhesion molecule that mediates the migration of immune cells to gut related immune tissues, and it is an important target for the treatment of IBD Founded in 2012 and headquartered in Toronto, Canada, cycle is a private biotechnology company The company has an advanced biotechnology platform, which can rapidly synthesize new macrocyclic peptides Macrocyclic peptide has unique physical and chemical properties, and has the potential to develop into a new generation of drugs, which has attracted extensive attention in the pharmaceutical industry In cooperation with several pharmaceutical companies, cycle has developed a macrocyclic peptide screening platform, laying a foundation for peptide drug research and development In addition, the company also develops oral biological preparations based on Smad ubiquitination regulator 2 (Smurf2) Smurf2 is a kind of E3 ubiquitin ligase, which has been found to be related to the development of pulmonary fibrosis It can selectively act on Smad Protein, regulate TGF - β 1 signal transduction of pulmonary fibrosis, and then regulate the development of pulmonary fibrosis Founded in 1998 and headquartered in Copenhagen, Denmark, Zeland Pharma is a leading biotechnology and pharmaceutical company The company is committed to the development of peptide therapy and related protein drugs to meet the clinical needs of patients With expertise in drug research and development, Zeland Pharma cooperates with Sanofi, Helsin and Boehringer Ingelheim, the world's leading pharmaceutical companies The company was listed on the Nasdaq Stock Exchange in August 2017 with the stock code of zel Emmanuel Dulac, President and CEO of Zeland Pharma, said: "we have rich experience in the research and development of cycle peptide drugs, and we are pleased to add et3764 to the peptide product line of Zeland pharma It is believed that this transaction will help Zealand Pharma consolidate its leading position in peptide drug development " Dr Jeffrey Coull, President and CEO of cycle, said: "cycle has been working on macrocyclic peptides Our research and development team has confirmed that the substance has great potential to regulate protein-protein interaction, which is difficult for small molecule regulation and biological regulation We are happy to join Zeland Pharma to help more patients recover " (original compilation: Xu Xiaoxue) this article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprinting is to transmit more information and does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.